{
    "clinical_study": {
        "@rank": "158011", 
        "arm_group": [
            {
                "arm_group_label": "Diabetic", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Non-diabetic", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the oral supplementation with curcumin reduces\n      proteinuria in patients with chronic kidney disease regardless the ethiology."
        }, 
        "brief_title": "Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Proteinuria", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Proteinuria", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Curcumin is a potent antioxidant found in extracts of the rhizome of the plant Curcuma longa\n      L.\n\n      Different studies have demonstrated that curcumin has potent biological activity and\n      therefore is an effective therapeutic agent for the treatment of various ailments.\n\n      This compound acts as a bifunctional antioxidant:\n\n      \u0647 is capable of reacting directly with highly reactive oxygen species. \u0647 acts indirectly by\n      its ability to induce the expression of various cytoprotective proteins through\n      Keap1/Nrf2/ARE pathway.\n\n      Although RAAS blockade is the cornerstone to prevent the progression of proteinuric\n      nephropathy, a significant number of patients remained with proteinuria and progress to\n      end-stage renal disease.\n\n      Due to the low cost and few side effects of curcumin, this could become an adjuvant\n      treatment of proteinuric nephropathy purposes attenuate the progression of chronic kidney\n      disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of proteinuric chronic kidney disease with 1g or more of proteins in a\n             daily recollection.\n\n          -  Individuals taking Angiotensin II Receptor Blocker or ACE inhibitors in monotherapy\n             with maximum dose or in combination.\n\n        Exclusion Criteria:\n\n          -  Hepatic damage.\n\n          -  Malignancy.\n\n          -  Pregnancy.\n\n          -  Peritoneal or hemodialysis.\n\n          -  Organ transplantation.\n\n          -  Heart failure classification III or IV (New York Heart Association).\n\n          -  History of chemotherapy within 2 years prior to screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831193", 
            "org_study_id": "12-793"
        }, 
        "intervention": {
            "arm_group_label": [
                "Diabetic", 
                "Non-diabetic"
            ], 
            "intervention_name": "Curcumin", 
            "intervention_type": "Drug", 
            "other_name": "Turmeric"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Curcumin", 
                "Turmeric extract"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 10, 2013", 
        "location": {
            "contact": {
                "email": "madero.magdalena@gmail.com", 
                "last_name": "Magdalena Madero, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Mexico city", 
                    "country": "Mexico", 
                    "state": "DF", 
                    "zip": "14080"
                }, 
                "name": "Instituto Nacional de Cardiologia Ignacio Chavez"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Mexico: National Institute of Public Health, Health Secretariat", 
                "Mexico: Secretaria de Salud"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in proteinuria", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831193"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Instituto Nacional de Cardiologia Ignacio Chavez", 
            "investigator_full_name": "Magdalena Madero", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Instituto Nacional de Cardiologia Ignacio Chavez", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto Nacional de Cardiologia Ignacio Chavez", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}